VacZine Analytics  
MarketVIEW: meningitis ABCWY vaccines

Published: Q4 2020

Neisseria meningitidis (N.men) is an important contributor to bacterial meningitis which can have a high fatality rate (up to 50% when untreated) and high frequency of severe sequelae (>10%). 5 main serogroups: ACWY and B are responsible for the majority of disease in Western countries with latest figures at: 3,233 cases of invasive disease in Europe (2018, ECDC figures) and 310 cases (0.09/100,000 persons) in the United States (ABC Surveillance, National Estimates). Rates of meningococcal disease are highest in infants <1 yrs and adolescent (16-23 yrs). Serogroup B disease predominates in children <5 yrs (US, CDC figures).

Historically, conjugated vaccines to prevent meningococcal disease have had successful impact, especially in the United Kingdom (serogroup C, implemented 1999) and the African meningitis belt with serogroup A vaccines: MenAfriVac (first implemented 2010). In 2005, a quadrivalent conjugated vaccine with protection against ACWY serogroups, Menactra (MCV4, Sanofi Pasteur) was recommended for use in US adolescents. Nimenrix (GSK, EU approved), Menveo (Novartis, FDA approved) and also Menactra (Sanofi Pasteur, FDA approved) are used in EU infants/toddlers (Malta) as well as adolescents in Czech Republic, Greece, UK, Netherlands and Austria. More recently, new serogroup B vaccines: Trumenba, Pfizer Vaccines and Bexsero, GSK Biologicals have been launched with UK being the first country in the world to have a routine infant program. The competitive situation has since intensified with GSK Biologicals and Pfizer developing new pentavalent meningococcal vaccines (PF-06886992 and GSK3536819A).

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for all conjugated and unconjugated A(B)CWY products within all age groups indications in the critical US market, EU5, LATAM and MENA regions for the next 10-15 years. The model includes BASE/HI forecast scenarios so the user can visualize the commercial impact of differing recommendation/competitive and pricing scenarios. The analysis also gives a latest review of disease epidemiology.

THIS PRODUCT IS A SUMMARY PRESENTATION (>100 slides, .pdf form) + 1 x FORECAST MODEL(s) (.xls)

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV009 Click here>> CONTACT US
*This is a licensed product. Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations). Please review the TERMS and CONDITIONS of purchase. Picture Credit: CDC (Unsplash)

Return to main list>> Questions about this report?






© 2020 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains